Details

Autor(en) / Beteiligte

• Holmberg, Scott D
• Spradling, Philip R
• Moorman, Anne C
• Denniston, Maxine M

Titel

Hepatitis C in the United States

Ist Teil von

• The New England journal of medicine, 2013-05, Vol.368 (20), p.1859-1861

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2013

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Recent analyses suggest that of the estimated 3.2 million people infected with hepatitis C virus, only about half have been tested and know their status, about a third have been referred for HCV care, and only 5 to 6% have been successfully treated. Care for hepatitis C is evolving rapidly, with increasingly effective and better-tolerated antiviral therapies being evaluated and approved for use. It's clear, however, that not everyone who would qualify for therapy has been tested and identified, referred for appropriate care, and offered or given the best therapy available. Furthermore, currently used antiviral drugs — pegylated interferon and ribavirin “base” plus either telaprevir or boceprevir — can cost more than $70,000 for a full course of therapy. It is expected that the new oral antiviral agents will be just as expensive, at least in the short term. All these factors affect . . .